Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Decernotinib

Next Previous
Drug Profile

Decernotinib

Alternative Names: Adelatinib; VRT-831509; VX-509

Latest Information Update: 02 Oct 2021

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Vertex Pharmaceuticals
  • Class Amides; Aminopyridines; Anti-inflammatories; Antirheumatics; Pyrimidines; Pyrroles; Small molecules
  • Mechanism of Action Janus kinase 3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 01 Jul 2014 Vertex completes a phase IIb trial in Rheumatoid arthritis in USA, Argentina, Bulgaria, Czech Republic, Estonia, Germany, Hungary, Mexico, Poland, Romania, Russia, Serbia, Slovakia and Ukraine (NCT01590459) prior to July 2015
  • 01 Feb 2014 Vertex Pharmaceuticals completes a phase II trial in Rheumatoid arthritis in USA, South Africa, the Netherlands, Denmark, Lithuania & Estonia (NCT01754935)
  • 21 Oct 2013 Interim safety and efficacy data from a phase IIb trial in Rheumatoid arthritis released by Vertex Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top